Clinical trials: Inhaled Nitric Oxide
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension Associated w/ COPD and IPF
The objective of this exploratory study is to examine the utility of high resolution computed tomography (HRCT) to measure changes in functional pulmonary imaging parameters as a function of short term a) iNO administration and…
- Conditions
- Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis
- Trial name
- NCT02267655
- Testing
- inhaled Nitric Oxide - 30 mcg/kg IBW/hr, inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr, inhaled nitric oxide 75 mcg/kg IBW/hr
- Where
- Belgium
- Volunteers
- 8 people
- Sponsor
- Bellerophon
Pulmonary Arterial Hypertension
Study of PAH Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled Nitric
Study of PAH Subjects with LTOT Use that have Demonstrated Improved Exercise Tolerance with the use of Inhaled Nitric Oxide
- Trial name
- NCT03602781
- Testing
- iNO
- Where
- 4 sites in United States, Canada
- Sponsor
- Bellerophon Pulse Technologies
Lung Disease, Hypoxemia
Inhaled Nitric Oxide in Neonates With Elevated A-a DO2 Gradients Not Requiring Mechanical Ventilation
The purpose of this pilot study is to evaluate whether administration of nitric oxide (NO)gas by oxygen hood at 20 ppm significantly increases PaO2, as compared to placebo gas (oxygen), within one hour of initiation and with no…
- Conditions
- Lung Disease, Hypoxemia, Respiratory Acidosis
- Trial name
- NCT00041548
- Testing
- nitric oxide for inhalation, Oxygen
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Mallinckrodt
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD
This is a placebo-controlled, double-blind, parallel, randomized, two-part, dose-confirming clinical study characterizing the pharmacodynamic effects of pulsed iNO using the combination product, inhaled nitric oxide/INOpulse DS-C…
- Trial name
- NCT01728220
- Testing
- Inhaled NO delivered via INOpulse DS-C Device
- Where
- 43 sites in United States
- Volunteers
- 159 people
- Sponsor
- Bellerophon Pulse Technologies
Persistent Pulmonary Hypertension of the Newborn, Hypoxic Respiratory Failure
Post Market Clinical Follow-up to Assess the Portable Nitric Oxide Generation and Delivery System (INOwill N200) for the Treatment of Neonatal Hypoxic Respiratory Failure Complicated by Pulmonary Hypertension
Title : A multicenter clinical trial of the portable nitric oxide generation and delivery system (INOwill N200) for the treatment of neonatal hypoxic respiratory failure complicated by pulmonary hypertension Investigational…
- Trial name
- iNOwill Neonat (NCT07837921)
- Testing
- Nitric Oxide Generator and Delivery System
- Volunteers
- 50 people
- Sponsor
- Novlead Inc.
High Altitude Pulmonary Hypertension
Inhaled Nitric Oxide for High Amplitude Pulmonary Edema (HAPE)
High Altitude Pulmonary Edema (HAPE) is a critical, non-cardiogenic pulmonary edema that manifests in high-altitude conditions, marked by the rapid onset of symptoms such as dyspnea, cough, frothy sputum, and cyanosis.
- Trial name
- HAPE (NCT06852924)
- Testing
- Nitric Oxide Generation and Delivery System
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Novlead Inc.
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution in Healthy Subjects
This is a four-part study of the safety, tolerability, and PK profile of sodium nitrite inhalation solution (AIR001) of ascending multiple doses (Part A) and of escalating doses with steady-state sildenafil (Part B) to healthy…
- Trial name
- NCT01409122
- Testing
- 15 mg sodium nitrite inhalation solution, 90 mg sodium nitrite inhalation solution, 45 mg sodium nitrite inhalation solution
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Aires Pharmaceuticals, Inc.
Pulmonary Fibrosis, Pulmonary Hypertension
A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
A randomized, double-blind, placebo-controlled dose escalation study to assess the safety and efficacy of pulsed, inhaled nitric oxide (iNO) in subjects with pulmonary fibrosis on long term oxygen therapy.
- Trial name
- NCT05747508
- Testing
- INOpulse®, Long Term Follow Up
- Where
- 23 sites in United States
- Volunteers
- 85 people
- Sponsor
- Bellerophon
Right Ventricular Infarction
The Effects of Nitric Oxide for Inhalation in Right Ventricular Infarction Patients
This study is designed to better understand the effects of nitric oxide, a gas for inhalation, on patients with right ventricular infarction.
- Trial name
- NCT00782652
- Testing
- inhaled nitric oxide, nitrogen gas
- Where
- 6 sites in United States, Belgium and 3 more
- Volunteers
- 3 people
- Sponsor
- Mallinckrodt
Ischemia-Reperfusion Injury
Inhaled Nitric Oxide in Prevention/Treatment of Ischemia-Reperfusion Lung Injury Related to Lung Transplantation
The purpose of this study is to evaluate the effects of inhaled nitric oxide on both short-term physiology as well as on the development of ischemia-reperfusion lung injury (IRLI) in the immediate post transplant period.
- Trial name
- NCT00060450
- Testing
- nitric oxide for inhalation
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Mallinckrodt
COVID-19, Coronavirus
A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of pulsed inhaled iNO compared to placebo in subjects with COVID-19.
- Conditions
- COVID-19, Coronavirus, Coronavirus Infection
- Trial name
- COViNOX (NCT04421508)
- Testing
- INOpulse
- Where
- 17 sites in United States
- Volunteers
- 191 people
- Sponsor
- Bellerophon Pulse Technologies
Chronic Obstructive Pulmonary Disease (COPD)
A Clinical Study of Inhaled Nitric Oxide in Patients With Chronic Obstructive Pulmonary Disease
This clinical trial aims to assess the impact on exercise tolerance and the safety of inhaled nitric oxide in subjects with moderate-to-severe COPD.
- Trial name
- NCT07382258
- Testing
- Nitric Oxide Generation and Delivery System
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Novlead Inc.
Pulmonary Hypertension, Hypoxic Respiratory Failure
Inhaled Nitric Oxide for the Treatment of Neonatal Hypoxic Respiratory Failure With Pulmonary Hypertension
This is a prospective, open-label, single-arm, multicenter Phase IV clinical study to evaluate the safety of INOmax for the treatment of hypoxic respiratory failure with pulmonary hypertension in newborns (≥ 34 weeks gestational…
- Trial name
- INOFTTONHRFWPH (NCT07099144)
- Testing
- Inhaled nitric oxide (NO)
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Lee's Pharmaceutical Limited
Hypoxic Respiratory Failure With Pulmonary Hypertension
Inhaled Nitric Oxide (INO) In Hypoxic Respiratory Failure
This Phase 3, Double-blind, Randomized, Placebo controlled, multicenter study is to confirm the efficacy of inhaled nitric oxide for the management of hypoxic respiratory failure associated with pulmonary hypertension in preterm…
- Trial name
- NCT00922532
- Testing
- Inhaled Nitric Oxide
- Sponsor
- Mallinckrodt
Cystic Fibrosis
Evaluation of the Safety and Tolerability of Inhaled Nitric Oxide to Subjects With Cystic Fibrosis
Cystic Fibrosis is defined as a genetic disorder affecting approximately 100,000 individuals worldwide. CF is caused by mutations in the CF Transmembrane Conductance Regulator (CFTR) gene.
- Trial name
- NCT01958944
- Testing
- Nitric oxide
- Where
- 2 sites in Israel
- Volunteers
- 9 people
- Sponsor
- Beyond Air Inc.
Pulmonary Arterial Hypertension
Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH
Phase 3, placebo controlled, double-blind, randomized clinical study to determine safety, tolerability, and efficacy of pulsed, inhaled nitric oxide (iNO) versus placebo in symptomatic subjects with pulmonary arterial…
- Trial name
- INOvation-1 (NCT02725372)
- Testing
- Inhaled Nitric Oxide 75 mcg/kg IBW/hr
- Where
- 109 sites in United States, Australia and 16 more
- Volunteers
- 207 people
- Sponsor
- Bellerophon Pulse Technologies
Coronavirus Infection, COVID-19
Pulsed Inhaled Nitric Oxide for the Treatment of Patients With Mild or Moderate COVID-19
The search for novel therapies to address the ongoing coronavirus (COVID-19) pandemic is ongoing. No proven therapies have been identified to prevent progression of the virus.
- Conditions
- Coronavirus Infection, COVID-19, Pneumonia, Viral
- Trial name
- NCT04358588
- Testing
- iNO (inhaled nitric oxide) delivered via the INOpulse Delivery System
- Sponsor
- Bellerophon
Asthma
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
This study is researching a drug called dupilumab. The study is focused on patients who have uncontrolled asthma. Asthma is a condition where the airways narrow and swell, making it difficult to breathe.
- Trial name
- AIM4:Next Step (NCT06572228)
- Testing
- dupilumab, ICS/LABA
- Where
- 77 sites in United States, Canada and 4 more
- Volunteers
- 120 people
- Sponsor
- Regeneron Pharmaceuticals
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
This is a Phase 2, Placebo Controlled, Double-Blind, Randomized, Clinical Study to Determine Safety, Tolerability and Efficacy of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo as Add-on Therapy in Symptomatic Subjects with…
- Trial name
- PAH (NCT01457781)
- Testing
- Inhaled Nitric Oxide 0.025 mg/kg IBW/hr delivered via INOpulse DS Device, Inhaled nitric oxide 0.075 mg/kg IBW/hr delivered via INOpulse DS Device
- Where
- 51 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- Bellerophon Pulse Technologies
Cystic Fibrosis
Safety and Tolerability of Inhaled Nitric Oxide in Patients With Cystic Fibrosis
The primary objective of the trial is to assess the safety and tolerability of inhaled nitric oxide (NO) when administered by nasal cannula over a 44 hour period to clinically stable Cystic Fibrosis (CF) subjects.
- Trial name
- NCT00570349
- Testing
- Nitric Oxide for Inhalation, Nitrogen
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mallinckrodt